Company Overview and News

 
D-Street Buzz: Nifty metal outperforms led by JSW Steel; Dish TV down 6%, BoB most active

14h moneycontrol
The Indian benchmark indices continues to trade on a positive note this Wednesday afternoon with the Nifty50 up 21 points and is trading at 11,300 while the Sensex is trading higher by 53 points at 37,343.
HINDCOPPER KOHINOOR MUTHOOTFIN PGEL 500325 500228 RELIANCE 532617 HNDZY HFCL 533398 NAUKRI 532777 533137 HCL-INSYS DEN 532221 500470 SONATSOFTW RIGD 500179 JSL GAILF BEL RLNIY SBAZ BHQRY HINDALCO 532508 533581 513599 JETAIRWAYS JSWSTEEL 533104 512559 HNDNF 500183 TTST TATASTEEL TATLY GAILY DCMSHRIRAM 500049 GLOBUSSPR 500440 500188 HINDZINC 523367

 
Over 70 stocks hit new 52-week high on BSE; Universal Cables, Globus Spirits jump 5-6%

2018-09-18 moneycontrol
The market trend has reversed this Tuesday morning with the Nifty50 up 12 points and is trading at 11,389 while the Sensex has gained 43 points and is trading at 37,628.
RMGALLOY SANPA 530807 GALLANTT AASHEE 516096 532726 DELTAMAGNT 519319 538634 533104 504286 532651 VRL 500365 GLOBUSSPR REGALIAA SPLIL UNIVCABLES 504212

 
Intellect Design, Tata Steel, Alembic Pharma top gainers among BSE Group A stocks

2018-09-12 moneycontrol
The Indian stock market traded higher on Wednesday afternoon with the Nifty50 up 78 points while the Sensex higher by 267 points at 37,680.
ABB 500008 500119 532504 RENUKA ARJQY AMARAJABAT 533104 500470 TTST TATASTEEL 532670 TATLY 500002 NAVINFLUOR ABBDY GLOBUSSPR DHAMPURSUG

 
Globus Spirits Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLOBUSSPR 533104

 
Globus Spirits Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLOBUSSPR 533104

 
Globus Spirits Limited - Investor Presentation

2018-08-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLOBUSSPR 533104

 
USL, GM Breweries, Pincon Spirit fall 5-6% after Karnataka govt raises excise duty on liquor

2018-07-05 moneycontrol
Share prices of all listed liquor companies fell up to 6 percent intraday on Thursday after the Karnataka government increased additional excise duty on liquor.
532432 538771 PINCON UBL UNITDSPR UQNTY UBHOLDINGS GLOBUSSPR 507458 UNBWY 532478 533104

 
Globus Spirits Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLOBUSSPR 533104

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...